SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.71+0.4%Dec 24 12:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: zeta1961 who wrote (10480)2/18/2004 3:50:50 PM
From: Biomaven  Read Replies (2) of 52153
 
FRX got approval for memantine for moderate/severe AD - it's been on the market for a few weeks now.

I know a neurologist that has been successfully using memantine for movement disorders (like tardive dyskinesia) for a while. My guess is that anything amantadine can do in this area memantine can do better. They are both non-competitive NMDA antagonists, although Amantadine's label is as an anti-viral. Structurally they are very similar (I think memantine has a couple of extra CH3 groups).

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News